Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed

详细信息    查看全文

• 作者：Reiner Schulte ; You-Suk Suh ; Ulrike Sauermann ; Washingtone Ochieng ; Sieghart Sopper ; Kwang S. Kim ; So-Shin Ahn ; Ki S. Park ; Nicole Stolte-Leeb ; Gerhard Hunsmann ; Young C. Sung ; Christiane Stahl-Hennig
• 关键词：SIV ; Mucosal immunization ; Adenovirus ; Vaccine ; Macaque
• 刊名：Virology
• 出版年：2009
• 出版时间：20 January 2009
• 年：2009
• 卷：383
• 期：2
• 页码：300-309
• 全文大小：892 K

文摘

We investigated the immunogenicity and efficacy of a bimodal prime/boost vaccine regimen given by various routes in the Simian immunodeficiency virus (SIV) rhesus monkey model for AIDS. Twelve animals were immunized with SIV DNA-vectors followed by the application of a recombinant adenovirus (rAd5) expressing the same genes either intramuscularly (i.m.) or by oropharyngeal spray. The second rAd5-application was given i.m. All vaccinees plus six controls were challenged orally with SIVmac239 12 weeks post-final immunization.

Both immunization strategies induced strong SIV Gag-specific IFN-γ and T-cell proliferation responses and mediated a conservation of CD4⁺ memory T-cells and a reduction of viral load during peak viremia following infection. Interestingly, the mucosal group was superior to the systemic group regarding breadth and strength of SIV-specific T-cell responses and exhibited lower vector specific immune responses. Therefore, our data warrant the inclusion of mucosal vector application in a vaccination regimen which makes it less invasive and easier to apply.